Xenon Pharmaceuticals Inc (XENE) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Xenon to Present at Stifel 2025 Virtual CNS Forum

VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc...

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and...

Xenon to Present at the 45th Annual TD Cowen Healthcare Conference

VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:...

Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities